| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5258510 | OTSUKA | Benzoheterocyclic compounds |
Nov, 2013
(10 years ago) | |
| US8501730 | OTSUKA | Process for preparing benzazepine compounds or salts thereof |
Sep, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5753677 | OTSUKA | Benzoheterocyclic compounds |
May, 2020
(3 years ago) | |
| US10905694 | OTSUKA | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
Apr, 2030
(5 years from now) | |
Samsca is owned by Otsuka.
Samsca contains Tolvaptan.
Samsca has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Samsca are:
- US5753677
- US5258510
Samsca was authorised for market use on 19 May, 2009.
Samsca is available in tablet;oral dosage forms.
Samsca can be used as method of treating hyponatremia.
Drug patent challenges can be filed against Samsca from 19 May, 2013.
The generics of Samsca are possible to be released after 07 April, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 19, 2014 |
Drugs and Companies using TOLVAPTAN ingredient
NCE-1 date: 19 May, 2013
Market Authorisation Date: 19 May, 2009
Treatment: Method of treating hyponatremia
Dosage: TABLET;ORAL
How can I launch a generic of SAMSCA before it's drug patent expiration?
More Information on Dosage
SAMSCA family patents
